1Cell.Ai Named Best Healthtech Startup 2026

Recognised for Innovation in Precision Oncology & Patient Impact

Read the Announcement
Request a Callback
  • Home
  • Solutions
  • Technology
  • Products

      Products

      Early-stage Treatment Selection

      OncoTarget®

      Targeted biomarker testing

      OncoHRD®

      HRD testing for PARP therapy

      OncoIndx 360® Endometrium

      Endometrial cancer profiling

      OncoPredikt® BRS

      Breast cancer recurrence risk asse..

      Advanced Precision Oncology

      OncoIndx® Multi-Modal

      Integrated DNA, RNA & Protein Pro..

      OncoIndx® Prime+

      Advanced comprehensive genomic..

      Monitoring & Response

      OncoMonitor® MRD

      Minimal residual disease monitoring

      OncoAlibrex®

      Treatment response monitoring

      Complementary Solutions

      OncoRisk®

      Hereditary cancer risk assessment

      IHC Biomarkers

      Comprehensive biomarker analys.

      DrG

      An AI-powered clinical workspace

  • Resources

      Resources

      Publication

      Peer-reviewed research and manuscripts

      Whitepapers & Reports

      In-depth technical analyses

      Guide & Explainers

      Educational content for all audiences

      FAQs

      Answers to common questions

      Case Studies

      Real-world clinical impact stories

      Expert Insights

      Articles and webinars from our team

      Newsletters

      Latest developments delivered to you

      Blogs

      Latest developments delivered to you

      We’ve just launched a new product!

      Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days. 

      Explore Oncolndx® 360° Endometrium
  • Press & News

      Press & News

      Press Releases

      Official announcements and statements

      In the News

      Media coverage and mentions

      Company Updates

      Latest news and developments

      Events & Conferences

      Events, talks, and participation

      Coming Soon

  • About Us

      About Us

      Our Mission 

      Why we do, what we do

      Our Team 

      Leadership, advisors, and board

      Our Lab 

      Certifications and capabilities

      Careers 

      Join our team

      We’re hiring!

      Media & Recognition 

      Awards and press coverage

  • Home
  • Solutions
  • Technology
  • Products

      Products

      Early-stage Treatment Selection

      OncoTarget®

      Targeted biomarker testing

      OncoHRD®

      HRD testing for PARP therapy

      OncoIndx 360® Endometrium

      Endometrial cancer profiling

      OncoPredikt® BRS

      Breast cancer recurrence risk asse..

      Advanced Precision Oncology

      OncoIndx® Multi-Modal

      Integrated DNA, RNA & Protein Pro..

      OncoIndx® Prime+

      Advanced comprehensive genomic..

      Monitoring & Response

      OncoMonitor® MRD

      Minimal residual disease monitoring

      OncoAlibrex®

      Treatment response monitoring

      Complementary Solutions

      OncoRisk®

      Hereditary cancer risk assessment

      IHC Biomarkers

      Comprehensive biomarker analys.

      DrG

      An AI-powered clinical workspace

  • Resources

      Resources

      Publication

      Peer-reviewed research and manuscripts

      Whitepapers & Reports

      In-depth technical analyses

      Guide & Explainers

      Educational content for all audiences

      FAQs

      Answers to common questions

      Case Studies

      Real-world clinical impact stories

      Expert Insights

      Articles and webinars from our team

      Newsletters

      Latest developments delivered to you

      Blogs

      Latest developments delivered to you

      We’ve just launched a new product!

      Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days. 

      Explore Oncolndx® 360° Endometrium
  • Press & News

      Press & News

      Press Releases

      Official announcements and statements

      In the News

      Media coverage and mentions

      Company Updates

      Latest news and developments

      Events & Conferences

      Events, talks, and participation

      Coming Soon

  • About Us

      About Us

      Our Mission 

      Why we do, what we do

      Our Team 

      Leadership, advisors, and board

      Our Lab 

      Certifications and capabilities

      Careers 

      Join our team

      We’re hiring!

      Media & Recognition 

      Awards and press coverage

x

    Request a Callback

    Fill in your details and our team will get in touch with you.


    • Biopharma
    • Oncologists
    • Researchers

    POLES-Precision Oncology Leadership Summit 2025

    • Mumbai, India
    Back to Event & Conferences

    Overview

    POLES 2025 marked a significant milestone in Indian precision oncology, bringing together leading clinicians, researchers, and policymakers from across South Asia. The event fostered meaningful collaboration, insightful discussions, and impactful policy recommendations, setting new benchmarks for innovation, clinical excellence, and the future direction of cancer care in the region.

    Highlight Video

    POLES 2025

    Summit Highlights

    Key Highlights

    • Policy whitepaper: Molecular tumor boards for all tertiary centers
    • First-ever POLES Oncology Champion Awards ceremony
    • Live NGS demonstration and diagnostic innovation showcase
    • International keynotes from MD Anderson and Princess Margaret Hospital

    Speakers

    David Carbone

    The Ohio State University Wexner Medical Center

    Kenneth Bloom

    Nucleai

    Ravindra Kolhe

    Augusta University

    Craig Gedye

    Genito-Urinary, Brain

    Charles Cobbs

    Neuro-Oncology

    David Gandara

    NSCLC and multi cancer

    David Gandara

    Providence Southern California

    Kavin Knoph

    Alameda Health System

    Chiara Cremolini

    Colorectal Cancer

    Razellel Kurzrock, MD

    General Oncology

    What Attendees Say

    “

    POLES 2025 was transformative. The policy discussions led to real follow-up at the ministry level. This is oncology advocacy at its finest.

    Dr. Rohan Kapoor

    Joint Director, Ministry of Health
    “

    POLES 2025 was transformative. The policy discussions led to real follow-up at the ministry level. This is oncology advocacy at its finest.

    Dr. Rohan Kapoor

    Joint Director, Ministry of Health
    “

    POLES 2025 was transformative. The policy discussions led to real follow-up at the ministry level. This is oncology advocacy at its finest.

    Dr. Rohan Kapoor

    Joint Director, Ministry of Health
    “

    The scientific rigor combined with the collaborative spirit made POLES 2025 the most impactful oncology conference I have attended in India.

    Prof. Sunita Das

    Head of Medical Oncology, PGIMER
    “

    The scientific rigor combined with the collaborative spirit made POLES 2025 the most impactful oncology conference I have attended in India.

    Prof. Sunita Das

    Head of Medical Oncology, PGIMER
    “

    The scientific rigor combined with the collaborative spirit made POLES 2025 the most impactful oncology conference I have attended in India.

    Prof. Sunita Das

    Head of Medical Oncology, PGIMER
    Close
    1Cell.Ai
    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.